Sona Nanotech Inc.

Recent News

  • Sona Signs MOU for Bovine TB Test Development and Commercialization

    Halifax, Nova Scotia--(Newsfile Corp. - November 8, 2022) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has entered into a memorandum of understanding ("MOU") to evaluate, and if determined effective, to commercialize its bovine tuberculosis ("BTB") rapid test. Under the terms of the MOU executed with Biotangents Limited ("Biotangents"), the parties plan to explore the characteristics of Sona's BTB test and its suitability for commercialization. Biotangents will provide Sona...

    2022-11-08 8:25 AM EST
  • Sona Announces Commercial Agreement with Siva Therapeutics

    This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021, to its short form base prospectus dated March 31, 2021.Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2022) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has entered into an agreement to supply certain gold nanorod material to Siva Therapeutics, Inc. ("Siva"), a developer of advanced, 'in-vivo' therapies for treating cancer.Siva...

    2022-10-20 9:02 AM EDT
  • Sona Provides Corporate Update

    Halifax, Nova Scotia--(Newsfile Corp. - May 19, 2022) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces the termination of its licensing agreement with Arlington Scientific for the Company's COVID-19 rapid saliva test following its analysis of data from two clinicial studies and consultations with the U.S. Food and Drug Administration ("FDA"). The studies included assessments of the test for both point-of-care ("POC") and for self-testing. The test achieved sensitivity of 88% in a...

    2022-05-19 5:27 PM EDT
  • Sona Announces Appointment of Two New Directors, Debt Settlement and Option Grant

    Halifax, Nova Scotia--(Newsfile Corp. - January 5, 2022) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce the appointment of Mr. Neil Fraser and Dr. Walter Strapps, Ph.D., to the Company's Board of Directors.Mr. Fraser is president of Medtronic Canada, a subsidiary of the global healthcare technology leader. He is a member of the University of British Columbia's School of Biomedical Engineering's Industry Advisory Committee and a member of the health...

    2022-01-05 8:42 AM EST
  • Sona Announces Research Collaboration with University of Toronto's Institute of Biomedical Engineering

    Halifax, Nova Scotia--(Newsfile Corp. - November 18, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce the launch of a new research program to explore the leading attributes of its unique, proprietary gold nanorod technology together with leading experts in the field of bioengineering.The Company has entered a collaboration with Dr. Warren Chan, distinguished professor, and Canada Research Chair in Nanobioengineering & Director of the Institute of Biomedical Engineering at the University...

    2021-11-18 8:02 AM EST
  • Sona Nanotech Grants Options

    Halifax, Nova Scotia--(Newsfile Corp. - November 12, 2021) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce that it has granted 1,000,000 incentive stock options to Officers and Directors under the Company's Stock Option Plan ("Option Plan"). Each option is exercisable into one common share at a price of $0.44 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms...

    2021-11-12 4:15 PM EST
  • Sona Announces U.S. Partnership and Preliminary Evaluation Results for Its COVID-19 Saliva Test

    Halifax, Nova Scotia--(Newsfile Corp. - November 8, 2021) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that it has entered into a binding licensing agreement with U.S. Food and Drug Administration ("FDA") registered Arlington Scientific Inc. ("ASI" or "Arlington") of Springville, Utah, an in-vitro diagnostics developer, manufacturer and distributor, to bring Sona's rapid saliva COVID-19 test to market. Under the terms of the agreement,...

    2021-11-08 3:27 PM EST
  • Sona Nanotech Grants Options

    Halifax, Nova Scotia--(Newsfile Corp. - September 29, 2021) - Sona Nanotech Inc. (CSE: SONA) (the "Company") is pleased to announce that it has granted 335,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 300,000 have been granted to a Director. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date...

    2021-09-29 3:57 PM EDT